Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
暂无分享,去创建一个
Jun Zhu | Akinyemi Aje | Salim Yusuf | Juliet Nakamya | Albertino Damasceno | Alben Sigamani | S. Yusuf | Jun Zhu | P. Pais | P. Janský | M. Ezekowitz | J. Healey | S. Connolly | A. Damasceno | A. Sigamani | W. Almahmeed | A. Avezum | J. Oldgren | P. Commerford | L. Wallentin | P. Reilly | Jonas Oldgren | Lars Wallentin | Stuart J Connolly | Alvaro Avezum | Prem Pais | Wael Almahmeed | A. Aje | Jeff S Healey | Jia Wang | Michael Ezekowitz | Patrick Commerford | Petr Jansky | Paul Reilly | Alex Grinvalds | Andrew Moriarty | J. Nakamya | Jia Wang | A. Moriarty | Alex Grinvalds | Á. Avezum
[1] D. Levy,et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.
[2] Kenneth A Ellenbogen,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Heart rhythm.
[3] Phalla Ou,et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. , 2007, The New England journal of medicine.
[4] F. McAlister,et al. Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.
[5] C. Camargo,et al. Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004. , 2008, Annals of emergency medicine.
[6] Basile Chaix,et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena , 2006, Journal of Epidemiology and Community Health.
[7] I. V. Van Gelder,et al. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry , 2014, Circulation.
[8] G. Lip,et al. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. , 2015, European heart journal.
[9] L. Williams,et al. Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by Neurological History and Examination , 2001, Stroke.
[10] G. Lip,et al. Added Predictive Ability of the CHA2DS2VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation: The Prospective Danish Diet, Cancer, and Health Cohort Study , 2012, Circulation. Cardiovascular quality and outcomes.
[11] Martin McKee,et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.
[12] Brown Wv. Framingham Heart Study. , 2011, Journal of clinical lipidology.
[13] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[14] M. Zubaid,et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): Design and Baseline Characteristics of Patients With Atrial Fibrillation in the Arab Middle East , 2011, Circulation. Cardiovascular quality and outcomes.
[15] J. Healey,et al. Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. , 2006, The Canadian journal of cardiology.
[16] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[17] G. Boriani,et al. 'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[18] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[19] É. Marijon,et al. Rheumatic heart disease , 2012, The Lancet.
[20] Kenneth A Ellenbogen,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.
[21] P. Wolf,et al. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.
[22] G. Breithardt,et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. , 2010, The American journal of cardiology.
[23] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[24] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[25] Silvia G Priori,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.
[26] F A Mathewson,et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.
[27] L. Chambers,et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP) , 2011, BMJ : British Medical Journal.
[28] T. Kural,et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. , 1996, The American journal of cardiology.
[29] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[30] Dietrich Andresen,et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.
[31] P. Armstrong,et al. Impact of specialist follow-up in outpatients with congestive heart failure , 2005, Canadian Medical Association Journal.
[32] G. Lip,et al. Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature , 2012, Circulation.
[33] G. Lip,et al. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry , 2013, PloS one.
[34] J. Tu,et al. Temporal trends in medication use and outcomes in atrial fibrillation. , 2013, The Canadian journal of cardiology.
[35] Stanley Nattel,et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.
[36] P. Wolf,et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke , 1978, Neurology.
[37] S. Raudenbush,et al. Predicting Risk-Adjusted Mortality for CABG Surgery: Logistic Versus Hierarchical Logistic Models , 2005, Medical care.
[38] P. Wolf,et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.
[39] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[40] Kenneth A Ellenbogen,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Heart rhythm.
[41] C. Atzema,et al. Patients with atrial fibrillation and an alternative primary diagnosis in the emergency department: a description of their characteristics and outcomes. , 2013, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[42] M. Zubaid,et al. Management and 1-Year Outcomes of Patients With Atrial Fibrillation in the Middle East , 2015, Angiology.
[43] B Neal,et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.
[44] P. Urban,et al. Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.